Immunotherapy of malignant gliomas: a modern view on the problem DOI Creative Commons
Arseniy Pichugin,

R. R. Kovyazina,

Albert Trondin

и другие.

Advances in molecular oncology, Год журнала: 2024, Номер 11(4), С. 23 - 40

Опубликована: Дек. 9, 2024

Malignant gliomas are one of the most common brain tumors in adults arising from glial cells with an extremely poor prognosis. Generally, therapy malignant consists radical surgical removal followed by radio- and/or chemotherapy. However, prognosis disease remains unfavorable.The review presents main clinical, morphological and molecular characteristics gliomas, their prognostic significance role choice targeted based on using tyrosine kinase inhibitors monoclonal antibodies. The current aspects immunotherapy (i.e., activation immune cells, or blockage immunosuppressive signaling) discussed detail. One well-known approaches cancer is checkpoint inhibitors. These drugs might be effective treatment overexpressing molecules that suppress functions. Another promising approach genetically modified CAR-T (CAR – chimeric antigen receptor) which identify eliminate cells. Cytokine also perspective approach, as well gene associated editing viral genes for production oncolytic viruses used anticancer vaccines. Vaccines being developed to generate specific antibodies recognized thereby stimulate system destroy tumor cells.Despite potential various methods, them at different stages preclinical clinical trials. Some demonstrate results good further use treat glioma patients.

Язык: Английский

Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities DOI Open Access
Shawyon Ezzati, S. Salib, Meenakshisundaram Balasubramaniam

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(4), С. 2316 - 2316

Опубликована: Фев. 15, 2024

Glioblastoma, a grade 4 glioma as per the World Health Organization, poses challenge in adult primary brain tumor management despite advanced surgical techniques and multimodal therapies. This review delves into potential of targeting epidermal growth factor receptor (EGFR) with small-molecule inhibitors antibodies treatment strategy. EGFR, mutationally active tyrosine kinase over 50% glioblastoma cases, features variants like EGFRvIII, EGFRvII missense mutations, necessitating deep understanding their structures signaling pathways. Although EGFR have demonstrated efficacy other cancers, application is hindered by blood–brain barrier penetration intrinsic resistance. The evolving realm nanodrugs convection-enhanced delivery offers promise ensuring precise drug to brain. Critical success identification patient populations that benefit from inhibitors. Tools radiolabeled anti-EGFR antibody 806i facilitate visualization conformations, aiding tailored selection. Recognizing synergistic combination therapies downstream targets mTOR, PI3k, HDACs pivotal for enhancing inhibitor efficacy. In conclusion, era precision oncology holds glioblastoma, contingent on treatments, effective navigation, exploration

Язык: Английский

Процитировано

24
Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment DOI Open Access
Natalia I. Agalakova

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(2), С. 945 - 945

Опубликована: Янв. 12, 2024

Chloroquine (CQ) and its derivate hydroxychloroquine (HCQ), the compounds with recognized ability to suppress autophagy, have been tested in experimental works clinical trials as adjuvant therapy for treatment of tumors different origin increase efficacy cytotoxic agents. Such a strategy can be effective overcoming resistance cancer cells standard chemotherapy or anti-angiogenic therapy. This review presents results combined application CQ/HCQ conventional drugs (doxorubicin, paclitaxel, platinum-based compounds, gemcitabine, tyrosine kinases PI3K/Akt/mTOR inhibitors, other agents) malignancies obtained experiments on cultured cells, animal xenografts models, few trials. The effects such an approach viability tumor growth, well autophagy-dependent -independent molecular mechanisms underlying cellular responses CQ/HCQ, are summarized. Although majority vitro vivo studies shown that effectively sensitize agents potential chemotherapy, often inconsistent. Nevertheless, pharmacological suppression autophagy remains promising tool increasing development more specific inhibitors is required.

Язык: Английский

Процитировано

13
Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives DOI
Jiyuan Liu, Fan Yang, Jinqu Hu

и другие.

CNS Neuroscience & Therapeutics, Год журнала: 2024, Номер 30(5)

Опубликована: Май 1, 2024

Abstract Gliomas are the most common primary tumors of central nervous system, with glioblastoma multiforme (GBM) having highest incidence, and their therapeutic efficacy depends primarily on extent surgical resection postoperative chemotherapy. The role intracranial blood–brain barrier occurrence drug‐resistant gene O6‐methylguanine‐DNA methyltransferase have greatly limited chemotherapeutic agents in patients GBM made it difficult to achieve expected clinical response. In recent years, rapid development nanotechnology has brought new hope for treatment tumors. Nanoparticles (NPs) shown great potential tumor therapy due unique properties such as light, heat, electromagnetic effects, passive targeting. Furthermore, NPs can effectively load drugs, significantly reduce side effects improve efficacy, showing chemotherapy glioma. this article, we reviewed mechanisms glioma drug resistance, physicochemical NPs, advances resistance. We aimed provide perspectives

Язык: Английский

Процитировано

11
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy DOI Creative Commons
Pankaj Garg, Sravani Ramisetty, Meera G. Nair

и другие.

Biochemical Pharmacology, Год журнала: 2025, Номер unknown, С. 116850 - 116850

Опубликована: Март 1, 2025

Breast cancer (BC) is a complex disease that affects millions of women worldwide. Its growing impact calls for advanced treatment strategies to improve patient outcomes. The PI3K/AKT/mTOR pathway key focus in BC therapy because it plays major role important processes like tumor growth, survival, and resistance treatment. Targeting this could lead better options present review explores how the becomes dysregulated BC, focusing on genetic changes PIK3CA mutations PTEN loss leads its aggravation. Current include use inhibitors targeting PI3K, AKT, mTOR with combination therapies showing promise overcoming drug improving effectiveness. Looking ahead, next-generation personalized plans guided by biomarker analysis may provide more accurate effective patients. Integrating these immunotherapy offers an exciting opportunity boost anti-tumor responses survival rates. This comprehensive summary current progress BC. It highlights future research directions therapeutic aimed at enhancing outcomes quality life.

Язык: Английский

Процитировано

0
Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches DOI

Gursimran Singh,

Rohit Rohit,

Pankaj Kumar

и другие.

Medical Oncology, Год журнала: 2025, Номер 42(4)

Опубликована: Март 10, 2025

Язык: Английский

Процитировано

0
Role of Extracellular vesicle microRNAs and RNA binding proteins on glioblastoma dynamics and therapeutics development DOI Creative Commons
Shilpi Singh, Clark C. Chen,

Stefan Kim

и другие.

Extracellular Vesicle, Год журнала: 2024, Номер 4, С. 100049 - 100049

Опубликована: Сен. 10, 2024

Язык: Английский

Процитировано

2
Mitochondrial Dysfunction: Effects and Therapeutic Implications in Cerebral Gliomas DOI Creative Commons
Gerardo Caruso, Roberta Laera, Rosamaria Ferrarotto

и другие.

Medicina, Год журнала: 2024, Номер 60(11), С. 1888 - 1888

Опубликована: Ноя. 18, 2024

Gliomas are the most common primary brain tumors, representing approximately 28% of all central nervous system tumors. These tumors characterized by rapid progression and show a median survival 18 months. The therapeutic options consist surgical resection followed radiotherapy chemotherapy. Despite multidisciplinary approach biomolecular role targeted therapies, progression-free is 6-8 incomplete tumor compliance with treatment due to several factors such as presence blood-brain barrier, numerous pathways involved in transformation, intra-tumoral mutations. Among these, interaction between mutations genes bio-energetic metabolism functional response has become protagonist studies. In this scenario, main played mitochondria, cellular organelles delimited double membrane containing their own DNA (mtDNA), which participates processes regulation metabolism, proliferation, apoptosis also source energy production. Therefore, it understood that mitochondrion, specifically its alteration, leading figure including acquisition mitochondrial cells subsequent identification so-called mitochondria-related (MRGs), both (mutation Complex I) structural (mutations III/IV), have been seen play an important metabolic reprogramming increased resistance apoptosis, tumorigenesis. This demonstrates these alterations could not only intrinsic biology but extrinsic one associated response. We aim summarize dysfunction interactions present gliomas how they might impact prognosis.

Язык: Английский

Процитировано

1
Immunotherapy of malignant gliomas: a modern view on the problem DOI Creative Commons
Arseniy Pichugin,

R. R. Kovyazina,

Albert Trondin

и другие.

Advances in molecular oncology, Год журнала: 2024, Номер 11(4), С. 23 - 40

Опубликована: Дек. 9, 2024

Malignant gliomas are one of the most common brain tumors in adults arising from glial cells with an extremely poor prognosis. Generally, therapy malignant consists radical surgical removal followed by radio- and/or chemotherapy. However, prognosis disease remains unfavorable.The review presents main clinical, morphological and molecular characteristics gliomas, their prognostic significance role choice targeted based on using tyrosine kinase inhibitors monoclonal antibodies. The current aspects immunotherapy (i.e., activation immune cells, or blockage immunosuppressive signaling) discussed detail. One well-known approaches cancer is checkpoint inhibitors. These drugs might be effective treatment overexpressing molecules that suppress functions. Another promising approach genetically modified CAR-T (CAR – chimeric antigen receptor) which identify eliminate cells. Cytokine also perspective approach, as well gene associated editing viral genes for production oncolytic viruses used anticancer vaccines. Vaccines being developed to generate specific antibodies recognized thereby stimulate system destroy tumor cells.Despite potential various methods, them at different stages preclinical clinical trials. Some demonstrate results good further use treat glioma patients.

Язык: Английский

Процитировано

0